What ProCentra Treats: Main Uses and Benefits

ProCentra is commonly used to provide symptomatic relief in clinical situations marked by chronic attentional deficits and severe wakefulness disorders, generally serving as supportive therapeutic benefit within a total treatment strategy. The active ingredient is used as part of a total treatment program to control symptoms of Attention-Deficit Hyperactivity Disorder (ADHD) and to treat Narcolepsy.

---

Symptomatic Relief and Therapeutic Focus

The therapeutic focus is primarily on managing core symptom clusters that interfere with daily functioning, specifically addressing persistent inattention, excessive hyperactivity, and debilitating Excessive Daytime Sleepiness (EDS). ProCentra is relevant for conditions presenting with disruptive symptom manifestations, namely ADHD and Narcolepsy. The support provided helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Quick Facts: Therapeutic Domains

Domain Focus	Symptom Category
Attention Deficits	Helps address groups of symptoms related to heightened neurological activity.
Wakefulness Disorders	Applied in situations involving symptoms related to systemic imbalance.
Pediatric Use	Relevant when supportive symptom management is appropriate for children.

Patient Benefit and Administration

ProCentra is commonly used when supportive symptom management is appropriate to address these symptoms. The support provided helps ease the overall symptom burden, and may help patients cope more steadily with symptom fluctuations when symptoms are more noticeable, supporting improved day-to-day comfort. The liquid oral solution formulation is specifically relevant for pediatric patients and others who face challenges swallowing solid tablets, which may assist with reliable access to the necessary therapeutic support.

“The medication contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

Regulatory References

1. Dextroamphetamine: MedlinePlus Drug Information

Who Can and Cannot Use ProCentra?

Regulatory agencies define specific population rules for the use of ProCentra (dextroamphetamine sulfate), classifying individuals who are eligible, restricted, or absolutely prohibited from using the medicine.

Contraindications (Must Not Use)

The medicine is strictly contraindicated in patients with a history of drug abuse, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, or agitated states. Use is also prohibited if the patient is currently taking or has taken a Monoamine Oxidase Inhibitor (MAOI) within the last mathbf14 days.

Age-Group Eligibility

The medication is approved for pediatric patients mathbf6 to mathbf16 years old for ADHD and mathbf6 years and older for Narcolepsy. For ADHD, use is also documented in children mathbf3 to mathbf5 years old. Use is not recommended in children under mathbf3 years of age, and safety and effectiveness in the geriatric population (mathbfge 65 years) have not been studied.

Conditional Use

The medicine is assigned Pregnancy Category C, meaning it should only be used if the potential benefit justifies the potential risk to the fetus. Furthermore, mothers taking the drug are advised to refrain from nursing as the active substance is excreted in human milk.

Interaction Map: Interactions with other medicines and products — official regulatory information for ProCentra

Interaction Scope

Category	Official Regulatory Documentation Statement
Medicinal product categories with documented interactions	Monoamine Oxidase Inhibitors (MAOIs), Serotonergic Drugs, CYP2D6 Inhibitors, Urinary and Gastrointestinal pH Modifiers, Adrenergic Blockers, Antihypertensives.
Specific interacting medicines (if explicitly listed)	Linezolid, intravenous Methylene Blue, Paroxetine, Fluoxetine, Quinidine, Ritonavir, Triptans, Tricyclic Antidepressants, Sodium Bicarbonate, Acetazolamide, Ammonium Chloride.
Mechanistic basis of interactions (only if stated in label)	Inhibition of metabolism via CYP2D6 (increasing exposure); Altered absorption and excretion via pH changes (increasing or decreasing exposure); Pharmacodynamic antagonism; Pharmacodynamic potentiation.
Timing-based interaction rules (if applicable)	Must not be administered during or within 14 days following the use of an MAOI.
Population-specific interaction notes (if applicable)	No population-specific interaction constraints are formally documented in the primary labeling.
Interaction-related restrictions	Contraindicated with MAOIs and agents with MAOI activity.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation Statement
Interaction severity classification (as defined in official documents)	Contraindicated (MAOIs); Clinically significant (Serotonergic drugs, CYP2D6 inhibitors, pH modifying agents).
Regulatory basis (EMA / FDA / etc.)	FDA-approved Prescribing Information.
Interaction-context constraints (as defined in official documents)	Interactions are classified based on the resulting outcomes, such as hypertensive crisis, serotonin syndrome, or altered plasma concentration.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a contraindicated combination due to the official risk of a severe hypertensive crisis.
• The regulatory label mandates a 14-day separation period after discontinuation of an MAOI before administration.
• pH-altering agents, such as urinary alkalinizing agents, formally increase the blood level of the active substance by decreasing its excretion.
• Acidifying agents (including certain fruit juices) officially lower the blood level of the drug by reducing absorption or increasing excretion.
• Co-administration with CYP2D6 inhibitors may formally increase exposure, raising the risk of serotonin syndrome.
• The effects of antihypertensives and adrenergic blockers may be antagonized by the active substance.

Connection to the overall interaction profile (3 sentences): The interaction profile is defined by a narrow focus on contraindicated combinations and several clinically significant pharmacokinetic and pharmacodynamic interactions. The structure details specific medicinal product classes and non-drug substances that alter drug concentration, primarily through documented effects on CYP2D6 metabolism and pH-dependent excretion. These statements serve as constraints for co-administration based on official regulatory outcomes like altered exposure or systemic adverse effects.

The pharmacological action of the active ingredient, Dextroamphetamine, is defined by a pronounced and rapid engagement with specific monoaminergic pathways, leading to increased central signaling. The mechanism involves multiple simultaneous molecular steps that substantially increase functional levels of key neurotransmitters, resulting in defined physiological changes.

Central Monoamine Efflux and Transporter Reversal

This mechanism is initiated by Dextroamphetamine targeting and reversing the function of the Dopamine Transporter (DAT) and Norepinephrine Transporter (NET), forcing the rapid efflux of these neurotransmitters out of the presynaptic neuron and into the synapse. This process, amplified by the inhibition of the internal Vesicular Monoamine Transporter 2 (VMAT2), ensures a substantial and sustained increase in the available signaling molecules.

Targeted Noradrenergic and Dopaminergic Pathway Augmentation

The elevated neurotransmitter levels specifically augment signaling within the dopaminergic circuits of the prefrontal cortex and the noradrenergic pathways tied to the Ascending Reticular Activating System (ARAS). This pathway augmentation increases the neural signal-to-noise ratio—the physiological basis for the capacity for cognitive control—while simultaneously promoting wakefulness and general alertness, influencing overall activity patterns.

Official Administration Guidelines

ProCentra (dextroamphetamine sulfate oral solution) is an immediate-release liquid formulation used via the oral route. Its administration follows a divided daily schedule to sustain the compound's effect throughout the day. The core principle of usage is to initiate treatment at the lowest effective dosage for the patient's condition and age group.

---

Dosing and Frequency

The total daily amount is typically divided into two or three doses, with a required interval of 4 to 6 hours between each administration. The first dose must be taken on awakening in the morning, and official instructions explicitly caution against late evening doses.

Indication (Age Group)	Initial Daily Dose	Titration Increment	Maximum Daily Dose (General)
ADHD (Ages 3 to 5 years)	2.5 mg daily	2.5 mg weekly	Not specified in this range
ADHD (6 years and older & Adults)	5 mg once or twice daily	5 mg weekly	40 mg (Rarely exceeded)
Narcolepsy (12 years and older)	10 mg daily	10 mg weekly	60 mg

Dosage adjustments are made weekly until the intended clinical response is achieved.

---

Procedural Use Constraints

The prescribing information also includes a procedural instruction for long-term use in treating Attention-Deficit Hyperactivity Disorder (ADHD): drug administration should be interrupted occasionally to formally evaluate the necessity for continued therapeutic support. This structured approach ensures that the use of the medicine remains appropriate for the patient's ongoing requirement. The liquid solution form requires no preparation or dilution steps for administration.

Research Evidence / Overview of Studies for ProCentra

---

Evidence for Use in Attention-Deficit Hyperactivity Disorder (ADHD)

The core evidence related to the study of this medicine for Attention-Deficit Hyperactivity Disorder (ADHD) primarily comes from short-term clinical trials. These studies, known as Randomized Controlled Trials (RCTs), involved observing pediatric and adult populations with ADHD over defined time intervals, typically lasting a few weeks. The research examined outcomes reflecting daily functioning or activity level in clinical situations where core ADHD symptoms are present, specifically monitoring changes in core symptoms such as inattention and hyperactivity/impulsivity. Standardized rating scales were used in research exploring how symptoms change over time.

Studies monitored how symptoms evolved in the observed populations, and the findings describe patterns observed during these short-term periods. This type of evidence contributes to understanding symptom patterns and is generally consistent across the aggregated trials. A key research limitation is the short follow-up duration of the pivotal RCTs, offering limited information for long-term outcomes.

---

Evidence for Use in Narcolepsy

The active ingredient in ProCentra was studied for use in Narcolepsy, a condition marked by functional limitations, particularly Excessive Daytime Sleepiness (EDS). This research has historically relied on clinical studies and more recent Randomized Controlled Trials (RCTs). The trials were relevant in evidence describing how symptoms are measured using both subjective and objective laboratory tests that monitor physiological strain related to alertness.

Studies observed how the medication was associated with changes in measures of wakefulness and alertness. Research describes patterns related to reducing the severity and frequency of episodic changes in wakefulness. The evidence for this indication appears to be moderate, given the reliance on both foundational studies and newer comparative research. Comparative evidence is lacking for certain scenarios, such as direct head-to-head research describing differences between the ProCentra liquid oral solution and every other existing immediate-release tablet form.

---

What Remains Uncertain or Under Study

Most of the available evidence is relevant in trials assessing short-term or episodic symptom patterns, and follow-up durations were limited in the controlled setting. Long-term effects are not fully established and there is limited information for long-term outcomes and the durability of effects. The results apply only to the populations studied, and subgroup findings are uncertain for those with complex comorbidities. The research provides context but findings describe group patterns, not personal outcomes.

Key Studies & References

1. Dextroamphetamine Sulfate Oral Solution, 5 mg/5 mL - FDA Approved Labeling/Prescribing Information
2. Attention Deficit Hyperactivity Disorder: Randomized Controlled Trials and Meta-Analysis of Stimulant Efficacy (General Evidence Base)

Common questions about ProCentra (FAQ)

Q: Is ProCentra the same as other medicines used for ADHD?

ProCentra contains dextroamphetamine sulfate, which belongs to the class of Central Nervous System (CNS) stimulants. While many medicines approved for ADHD share this classification, ProCentra is specifically offered as an immediate-release liquid oral solution, which is a key distinguishing feature of the product.

---

Q: Are there any specific foods to avoid when taking ProCentra?

Official product information states that certain acidifying agents can lower the amount of medicine absorbed into the blood, potentially reducing effectiveness. This includes substances found in some fruit juices. Conversely, alkalinizing agents may increase the blood level. The presence of these substances is described as affecting how the medicine works.

---

Q: Does ProCentra interact with common antidepressants?

Regulatory documents list interactions with several drug categories that include common antidepressants, such as Serotonergic Drugs and CYP2D6 Inhibitors. Combining ProCentra with these can increase the risk of serious conditions like Serotonin Syndrome. Interaction review remains the responsibility of the prescribing professional.

---

Q: Is ProCentra safe for use in children?

ProCentra is FDA-approved for ADHD treatment in children as young as 3 years old. However, official information notes a potential safety concern of long-term growth suppression (in height and weight) associated with chronic use in pediatric patients. Monitoring of growth is a procedural step described in the product information.

---

Q: What does the FDA say about the long-term use of ProCentra?

The official administration guidelines for long-term ADHD treatment include a procedural instruction that the administration of the drug should be interrupted occasionally. This formal interruption allows a healthcare professional to re-evaluate the ongoing need for continued therapeutic support.

---

Q: Is ProCentra known to cause anxiety or nervousness?

Official adverse reaction reports document nervousness as a common side effect of the active ingredient. Other related Central Nervous System effects, such as agitation, restlessness, and dizziness, are also noted in the product information.

---

Q: Can ProCentra impact vision or cause dry mouth?

The regulatory label lists dry mouth (xerostomia) as a frequently documented adverse reaction. Additionally, side effects related to eyesight, specifically blurred vision, have been reported. Changes in vision are among the adverse reactions for which official documents recommend seeking professional medical attention.

---

Q: How do doctors monitor patients taking ProCentra?

When taking this medication, official regulatory documents advise monitoring several key health indicators. These include checking blood pressure and heart rate regularly, monitoring growth (height and weight) frequently in children, and watching for the emergence of new psychiatric symptoms.

---

Q: How quickly does ProCentra typically start working?

ProCentra is formulated as an immediate-release oral solution, meaning the active substance is immediately available for absorption after administration. The typical dosing schedule involves divided doses with an interval of 4 to 6 hours, which is related to the duration of the clinical effect.

---

Q: What is the difference between ProCentra and Adderall?

ProCentra is an immediate-release liquid solution that contains dextroamphetamine sulfate as its single active ingredient. It is classified as a Central Nervous System (CNS) stimulant. Official regulatory sources focus only on the specific composition and properties of ProCentra.

---

Q: How long do the effects of a single dose of ProCentra last?

The drug is an immediate-release formulation, and the administration guidelines recommend a daily dose be divided, with a typical interval of 4 to 6 hours between each administration. This interval helps sustain the compound’s effect throughout the day.

---

Q: Does ProCentra lose its effectiveness over time (tolerance)?

Yes, official product information acknowledges that the active substance may produce tolerance. Tolerance is a physiological state in which the body adapts to the medication, and a higher dose may be required to achieve the same effect that was previously achieved with a lower dose.

---

Q: What happens if I miss a scheduled amount of ProCentra?

If a dose is missed and it is nearly time for the next scheduled dose, patient guidance describes skipping the missed dose and returning to the regular schedule. Taking double the amount is explicitly cautioned against in regulatory guidance.

---

Q: Is there a generic version of ProCentra available?

Yes, official product information confirms that an Authorized Generic version of the dextroamphetamine sulfate oral solution is available in the market.

---

Q: Can a person stop taking ProCentra suddenly?

The regulatory label indicates that the medication may produce physical dependence with prolonged use. Abrupt discontinuation or a major reduction in the amount taken can lead to withdrawal signs and symptoms, which may include fatigue, depression, or dysphoric mood.

---

Q: Does ProCentra interact with caffeine or energy drinks?

The active substance is classified as a Central Nervous System (CNS) stimulant. While specific interaction warnings for caffeine are not listed, combining this drug with other CNS stimulants can lead to the potentiation of effects. This change is indicated by official sources to potentially increase the risk of cardiovascular side effects.

---

Q: Are there different strengths of ProCentra available?

The ProCentra oral solution is supplied in a single concentration. Its strength is listed as 5 mg of dextroamphetamine sulfate per 5 mL of solution, according to the official Dosage Forms and Strengths section of the label.

---

Q: Can ProCentra be taken with cold or flu medicines?

Official interaction guidance notes that the drug may reduce the sedative effects of certain cold medicine ingredients, specifically antihistamines. Additionally, some over-the-counter cold and flu products contain stimulants that may increase the effect of ProCentra. The potential for increased effect is a documented consideration when reviewing co-administration.

---

Q: Is it normal to feel tired when the effects of ProCentra wear off?

Official information regarding the abrupt discontinuation of the active substance notes that fatigue and hypersomnia (excessive sleepiness) can be symptoms. This indicates a potential effect related to the offset of the medication's action.

---

Q: Are there any known interactions between ProCentra and alcohol?

Yes, official patient information advises against the use of the active ingredient with alcohol. This combination is stated to increase the risk of cardiovascular side effects, such as changes in heart rate or blood pressure.

---

Q: What is the difference between ProCentra and Vyvanse?

ProCentra is an immediate-release liquid solution that contains only dextroamphetamine sulfate. It is a Central Nervous System (CNS) stimulant. Official regulatory sources focus only on the specific composition and formulation of ProCentra.

---

Q: Does ProCentra have a black box warning?

Yes, the product is required by the FDA to carry a Boxed Warning. This warning is intended to alert users to the serious risk of abuse, misuse, and addiction, which can lead to overdose and death.

---

Q: What are the signs of too much ProCentra in the body?

Symptoms of too much ProCentra are documented in the Overdosage section of the label. These symptoms can include effects on the central nervous system, such as agitation, confusion, or seizures, and serious cardiovascular effects, including high blood pressure or irregular heart rhythms. Life-threatening hyperthermia is also noted as a risk.

---

Q: Can people with kidney or liver problems use ProCentra?

Regulatory guidance advises that caution should be used when prescribing the medicine to older adults who may have age-related liver or kidney function decline. Furthermore, use is generally not recommended in patients who have severe kidney disease.

---

Q: Does ProCentra have any known interactions with herbal supplements?

The drug is known to interact with serotonergic agents, a category that can include certain herbal supplements. For example, the use of St. John's Wort is noted to carry an increased risk of Serotonin Syndrome when combined with the active ingredient.

---

Q: Why must ProCentra be dispensed with a special guide (Medication Guide)?

The FDA requires that ProCentra be dispensed with an official Medication Guide. This requirement is in place because the product is considered to be a serious public health concern related to the risk of abuse, misuse, and addiction.

---

Q: Is dizziness or lightheadedness a reported side effect of ProCentra?

Yes, dizziness is listed as a documented side effect related to the Central Nervous System. Additionally, other side effects such as faintness or lightheadedness when changing position have been reported in association with the active ingredient.

---

Q: Can I take over-the-counter pain relievers while using ProCentra?

Official regulatory documents do not list specific major warnings against common over-the-counter pain relievers like acetaminophen or ibuprofen. However, due to general interaction potential, especially with certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs), reviewing the full drug interaction profile remains the responsibility of the prescribing professional.

How to Store and Dispose of ProCentra (Dextroamphetamine Sulfate Oral Solution)

Item	Official Requirement
Storage Temperature	Store at Controlled Room Temperature, 68^circ to 77 F (20^circ to 25 C).
Protection	Must be protected from light and dispensed in a tight, light-resistant container.
Security & Safety	Keep in a safe place, preferably locked, to protect from theft. Keep out of the reach of children.
Disposal (Primary)	Dispose of unused or expired solution via a medicine take back program at a DEA authorized collection site.
Disposal (Alternative)	If no take back program is available, mix the solution with an undesirable, nontoxic substance (e.g., dirt, cat litter). Place the mixture in a sealed plastic bag and discard it in household trash.

Official regulatory documents define storage to maintain stability, requiring the solution to be kept at a controlled temperature and shielded from light. Its classification as a Schedule II controlled substance mandates that the medication be stored securely in a locked location and kept away from children. Formal disposal instructions require a drug take-back program or a specific method to render the unused solution unusable before disposal.